Drugs / huJ591
huJ591
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02693860 | Feb 2016 → Feb 2017 | prostate cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1 | NCT02552394 | Jul 2015 → Nov 2019 | prostate cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00195039 | Aug 2004 → Feb 2012 | prostate cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT00024232 | Jun 2001 → Feb 2004 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00040586 | — | prostate cancer | BZL Biologics | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02410577 | Apr 2015 → Aug 2018 | glioblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-07 | GrandPharma (China) Co., Ltd. | Regulatory 再传捷报！远大医药全球创新RDC产品TLX591加入国际多中心III期临床试验的申请已获国家药监局受理 grandpharm.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-07 | GrandPharma (China) Co., Ltd. | 再传捷报！远大医药全球创新RDC产品TLX591加入国际多中心III期临床试验的申请已获国家药监局受理 grandpharm.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HuJ591 | “177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)” NCT00195039 ↗ |
| Known as | 177Lu-J591 | “177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)” NCT00195039 ↗ |
| Known as | J591 | “Pilot Trial of Humanized Monoclonal Antibody J591 in Patients With Progressive Androgen-Independent Prostate Cancer” NCT00024232 ↗ |
| Action | Deplete | “The purpose of this study is to treat patients with an experimental antibody (i.e. that has not been FDA approved) called J591 that attaches itself to a special protein on...” NCT02552394 ↗ |
| Modality | Monoclonal antibody | “Determine the antitumor effects of monoclonal antibody huJ591 in patients with progressive androgen-independent prostate cancer.” NCT00024232 ↗ |
| Route | Intravenous | “Patients receive monoclonal antibody huJ591 IV followed by indium In 111 monoclonal antibody huJ591 on day 1.” NCT00024232 ↗ |